ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence.

Wedad H Alotaibi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.